Diffúz nagy B-sejtes limfóma (DLBCL): vizsgálatok itt: Kanada
16 trials · From ClinicalTrials.gov, checked 2026. november 11.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- Where
- Edmonton, Halifax, Hamilton, Oshawa, Toronto
- Életkor
- 18 év and over
- People
- 1046 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06717347 · EU 2024-515566-13-00 - 2. fázisTaking peopleEvaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
- Where
- Calgary, Winnipeg
- Életkor
- 18 év and over
- People
- 130 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT06806033 · EU 2024-516791-15-00 - 3. fázisTaking peopleA Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- Where
- Toronto
- Életkor
- 18 év and over
- People
- 400 worldwide
- Run by
- Lyell Immunopharma, Inc.
See details and how to joinNCT07188558 - 2/3. fázisTaking peopleA Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
- Where
- Toronto
- Életkor
- 18 év and over
- People
- 290 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT05139017 · EU 2022-502646-27-00 - 1. fázisTaking peopleIKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas
- Where
- Montreal
- Életkor
- 18 év and over
- People
- 140 worldwide
- Run by
- Iksuda Therapeutics Ltd.
See details and how to joinNCT05365659 - 1/2. fázisTaking peopleSubstudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Where
- Calgary, Montreal, Toronto
- Életkor
- 6 hónap to 25 év
- People
- 90 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06395103 · EU 2023-507178-41-00 - 2. fázisTaking peopleConsolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
- Where
- Calgary, Halifax, Montreal, Québec, Toronto
- Életkor
- 18 év and over
- People
- 250 worldwide
- Run by
- Allogene Therapeutics
See details and how to joinNCT06500273 - 1. fázisTaking peopleCLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies
- Where
- Calgary, Ottawa, Toronto, Vancouver
- Életkor
- 1 év and over
- People
- 24
- Run by
- British Columbia Cancer Agency
See details and how to joinNCT06208735 - 1/2. fázisTaking peopleA Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Where
- Calgary, Edmonton, Québec, Toronto, Vancouver
- Életkor
- 18 év and over
- People
- 689 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT05006716 · EU 2022-502157-33-00 - No phaseTaking peoplePreliminary Assessment of [18F]BL40 in PET/CT Scans
- Where
- Vancouver
- Életkor
- 19 év to 100 év
- People
- 30
- Run by
- British Columbia Cancer Agency
See details and how to joinNCT06224309 - 3. fázisTaking peopleStudy of Out of Specification for Tisagenlecleucel
- Where
- Hamilton, Montreal, Ottawa, Québec, Toronto
- Életkor
- 0 év to 100 év
- People
- 200 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT04094311 - 2. fázisTaking peopleDALY II USA/ MB-CART2019.1 for DLBCL
- Where
- Edmonton, Toronto
- Életkor
- 18 év and over
- People
- 315 worldwide
- Run by
- Miltenyi Biomedicine GmbH
See details and how to joinNCT04792489 · EU 2023-508508-39-01 - 2. fázisTaking peopleFeasibility Trial of Glofitamab in a Response Adapted Approach Incorporating Interim FDG PET and ctDNA to Optimize Primary Therapy of DLBCL (GRAIL)
- Where
- Montreal, Toronto
- Életkor
- 18 év and over
- People
- 40
- Run by
- University Health Network, Toronto
See details and how to joinNCT06050694 - No phaseTaking peopleReal-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With Diffuse Large B-Cell and Follicular Lymphoma
- Where
- Edmonton, Greater Sudbury, Kingston, Moncton, St. John's
- Életkor
- 18 év and over
- People
- 700 worldwide
- Run by
- AbbVie
See details and how to joinNCT06830759 - 1. fázisTaking peopleOptimizing lymphoDepletion to Improve Outcomes In Patients Receiving Cell Therapy With Yescarta
- Where
- Toronto
- Életkor
- 18 év and over
- People
- 40
- Run by
- University Health Network, Toronto
See details and how to joinNCT05950802 - 2. fázisTaking peopleDPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Where
- Saskatoon
- Életkor
- 18 év and over
- People
- 102 worldwide
- Run by
- ImmunoVaccine Technologies, Inc. (IMV Inc.)
See details and how to joinNCT04920617